	US 12,303,550 B2
	Neuroprotective peptides
Bruno Meloni, Mount Hawthorn (AU)
Assigned to ARGENICA THERAPEUTICS PTY LTD, Nedlands (AU)
Filed by ARGENICA THERAPEUTICS PTY LTD, Nedlands (AU)
Filed on Dec. 20, 2021, as Appl. No. 17/556,730.
Application 17/556,730 is a division of application No. 16/041,483, filed on Jul. 20, 2018, granted, now 11,229,678.
Application 16/041,483 is a division of application No. 14/392,392, abandoned, previously published as PCT/AU2014/050326, filed on Oct. 30, 2014.
Claims priority of application No. 2013904197 (AU), filed on Oct. 30, 2013; and application No. 2014902319 (AU), filed on Jun. 17, 2014.
Prior Publication US 2022/0111003 A1, Apr. 14, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01); A61P 9/10 (2006.01); A61P 21/00 (2006.01); A61P 25/02 (2006.01); A61P 25/16 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 9/0053 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/001 (2013.01); A61K 38/00 (2013.01); A61P 9/10 (2018.01); A61P 21/00 (2018.01); A61P 25/02 (2018.01); A61P 25/16 (2018.01)]

12 Claims

1. A method of treating a surgery patient at risk of suffering cerebral ischemia or stroke, the method comprising intravenously administering to the surgery patient, 0.25 hours to 4 hours prior to the surgery, a pharmaceutical composition comprising an effective amount of a poly-arginine peptide having 12 to 18 arginine residues, wherein the pharmaceutical composition does not contain an active pharmaceutical ingredient that is not a poly-arginine peptide.